{"title": "Pedro Lowenstein, M.D., Ph.D. Publications | Neurosurgery | Michigan Medicine", "author": null, "url": "https://medicine.umich.edu/dept/neurosurgery/pedro-lowenstein-md-phd-publications", "hostname": "umich.edu", "description": "2022 Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression.", "sitename": "Neurosurgery", "date": "2020-09-23", "cleaned_text": "as an actionable target to disrupt tumor progression. Comba A, Faisal A, Kleer CG, Motsch Commun. 2022 Jun 24;13(1):3606. doi: [10.1038/s41467-022-31340-1](http://www.doi.org/10.1038/s41467-022-31340-1) Systemic Delivery of Synthetic JA, Carney S, Comba A, Faisal SM, Barissi M, Edwards MB, Appelman H, Sun Y, Gan J, Ackermann R, Schwendeman A, Candolfi M, Olin MR, Lahann J, Lowenstein PR, MG. ACS Nano. May 26. doi: [10.1021/acsnano.1c07492](http://www.doi.org/10.1021/acsnano.1c07492) BL, Alghamri MS, Thalla STAR Protoc. 2022 May 25;3(2):101357. doi: [10.1016/j.xpro.2022.101357](http://www.doi.org/10.1016/j.xpro.2022.101357) Therapeutic diffuse midline glioma. Messinger D, Harris MK, Cummings JR, Thomas C, Yang T, Sweha SR, Woo R, Siddaway R, Burkert M, Stallard S, Qin T, Mullan R, NA, Schmidt SV, Spitzer J, Jiang L, Filbin MG, Cao X, Castro MG, Lowenstein PR, Mody R, Chinnaiyan A, Desprez PY, McAllister phase transition and ATM inhibitor radio-sensitization. Qin T, Mullan B, Ravindran R, Messinger D, Siada R, Cummings JR, Harris M, Muruganand A, Pyaram K, Miklja Z, Reiber M, Garcia T, Tran D, Danussi C, Brosnan-Cashman J, Pratt D, Zhao X, A, Sartor MA, Venneti S, Meeker AK, Huse MA, Lowenstein PR, Castro MG, immunosuppression and of immunotherapy. Alghamri MS, McClellan BL, Avvari RP, Thalla MS, Haase S, Ventosa M, Taher A, Kamran PG, Eddy K, Merajver SD, Ulintz PJ, Welch J, Gao C, Liu J, N\u00fa\u00f1ez G, Hambardzumyan D, Lowenstein PR, Castro to Therapeutic Comba Andrea, Syed M., R. Front. Oncol., 05 Aug 2021 DOI: [10.3389/fonc.2021.703764](https://doi.org/10.3389/fonc.2021.703764) A novel miR1983-TLR7-IFN circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1. Shah D, Comba A, Faisal SM, Kadiyala P, Baker GJ, Alghamri MS, Doherty R, Zamler D, Nu\u00f1ez G, Lowenstein PR. Oncoimmunology. 28;10(1):1939601. DOI: [10.1080/2162402X.2021.1939601](https://www.doi.org/10.1080/2162402X.2021.1939601) Genetic Alterations and Impact Immune-Mediated Therapies. Garcia-Fabiani MB, Haase S, Comba A, Carney S, McClellan B, Banerjee K, Alghamri MS, Syed F, Kadiyala P, Nunez FJ, Candolfi M, Asad A, Gonzalez N, Aikins ME, Schwendeman A, Moon JJ, Lowenstein PR, Castro MG. Front Oncol. 2021 Jun 8;11:631037. DOI: [10.3389/fonc.2021.631037](https://www.doi.org/10.3389/fonc.2021.631037) Targeting Neuropharmaceutical Developments. Alghamri SV, Mujeeb AA, Olin MR, Moon JJ, Schwendeman A, Lowenstein Castro MG. Front Pharmacol. 2021 May 18;12:680021. DOI: [10.3389/fphar.2021.680021](https://www.doi.org/10.3389/fphar.2021.680021) Current K, N\u00fa\u00f1ez FJ, Haase McClellan BL, Faisal MS, Asad AS, Candia AJN, Varela ML, Candolfi M, PR, Therapeutic Opportunities. Haase S, Nu\u00f1ez FM, Gauss JC, Thompson S, Brumley E, Lowenstein P, Castro MG. Int J Mol Sci. 2020 Dec 17;21(24):E9654. DOI: [10.3390/ijms21249654](https://www.doi.org/10.3390/ijms21249654) Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas. Faisal SM, Mendez FM, Nunez F, Garcia-Fabiani MB, Haase S, Alghamri MS, N\u00fa\u00f1ez FJ, Liu Y, Yu M, Taher AW, Nunez FM, Li D, Edwards MB, Kleer CG, Appelman H, Sun Y, Zhao L, Moon JJ, Schwendeman A, Lowenstein PR, Castro MG. J Clin Invest. 2020 Dec 17:139542. DOI: [10.1172/JCI139542](https://www.doi.org/10.1172/JCI139542) Genetically FM, Gauss JC, Mendez FM, Haase Castro MG. STAR Protoc. 2020 Nov 25;1(3):100165. DOI: [10.1016/j.xpro.2020.100165](https://www.doi.org/10.1016/j.xpro.2020.100165) Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Gregory JV, Kadiyala P, Doherty R, Cadena M, Habeel S, Ruoslahti E, Lowenstein PR, Castro MG, Lahann J. Nat Commun. 2020 Nov 10;11(1):5687. DOI: [10.1038/s41467-020-19225-7](https://www.doi.org/10.1038/s41467-020-19225-7) An Optimized Protocol for In Vivo Analysis of Tumor Cell Division in a Sleeping Beauty-Mediated Mouse Glioma Model. Garcia-Fabiani MB, Kadiyala P, Lowenstein PR, Castro MG. Sep DOI: L, P, Sun X, Son S, Hassani Najafabadi A, Aikins M, Lowenstein PR, Schwendeman A, Castro MG, Moon JJ. Clin Cancer Res. 2020 Aug 15;26(16):4369-4380. DOI: [10.1158/1078-0432.CCR-20-0341](https://www.doi.org/10.1158/1078-0432.CCR-20-0341) Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy. Sperry J, Condro MC, Guo L, Braas D, Vanderveer-Harris N, Kim KKO, Pope WB, Divakaruni AS, Lai A, Christofk H, Castro MG, Lowenstein PR, Le Belle JE, Kornblum HI. iScience. 2020 Aug 13;23(9):101453. DOI: Kinase 3 High-Grade Brainstem Glioma. Mendez F, Kadiyala Gauss JC, Ravindran R, Pawar S, Edwards M, Garcia-Fabiani MB, Haase S, Lowenstein PR, Castro MG. Clin Cancer Res. 2020 Aug 1;26(15):4080-4092. DOI: [10.1158/1078-0432.CCR-19-3714](https://www.doi.org/10.1158/1078-0432.CCR-19-3714) Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Zhou W, Yao Y, Scott AJ, Wilder-Romans K, Dresser JJ, Werner CK, Sun H, Pratt D, Sajjakulnukit P, Zhao SG, Davis M, Nelson BS, Halbrook CJ, Zhang L, Gatto F, Umemura Y, Walker AK, Kachman M, Sarkaria JN, Xiong J, Morgan MA, Rehemtualla A, Castro MG, Lowenstein P, Chandrasekaran S, Lawrence TS, Lyssiotis CA, Wahl DR. Jul 30;11(1):3811. DOI: [10.1038/s41467-020-17512-x](https://www.doi.org/10.1038/s41467-020-17512-x) Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development. Garcia-Fabiani MB, Ventosa M, Comba A, Candolfi M, Nicola Kadiyala P, Carney S, Faisal SM, Schwendeman A, Moon JJ, Scheetz L, Lahann J, Mauser A, Lowenstein PR, Castro MG. Jul;29(7):659-684. DOI: Ventosa M, Patel P, Zamler DB, FJ, Zhao L, Castro MG, Ventosa M, Patel P, Zamler DB, FJ, Zhao L, Castro MG, 2020 May 19:noaa063. DOI: [10.1093/neuonc/noaa063](https://www.doi.org/10.1093/neuonc/noaa063) Self-organization in How cell morphology cell density influence glioma pattern formation. Jamous S, Comba A, Lowenstein Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion. Comba A, Dunn PJ, Kish PE, Kadiyala P, Kahana A, Castro MG, Lowenstein PR. J Vis Exp. 2020 Apr 12;(158):10.3791/60939. DOI: [10.3791/60939](https://www.doi.org/10.3791/60939) Tumor mutational burden predicts in gliomas expressing mutated IDH1. Alghamri MS, Thalla Dabaja A, Taher A, Zhao L, Ulintz PJ, Castro MG, Lowenstein PR. Neurooncol Adv. 2020 Mar 27;2(1):vdaa042. DOI: [10.1093/noajnl/vdaa042](https://www.doi.org/10.1093/noajnl/vdaa042) Kadiyala MB, Asad AS, Nicola Candia AJ, Candolfi M, Lahann J, Moon JJ, Schwendeman A, Lowenstein PR, disease. Mendez FM, N\u00fa\u00f1ez MB, Haase S, Carney S, Gauss JC, Becher OJ, Lowenstein PR, Castro MG. Neuro Oncol. 2020 Feb 20;22(2):195-206. DOI: [10.1093/neuonc/noz218](https://www,doi.org/10.1093/neuonc/noz218) Isolation and characterization of immune cells from the tumor microenvironment of genetically engineered pediatric high-grade glioma models using the sleeping beauty transposon system. Garcia-Fabiani Comba A, Kadiyala P, Haase S, N\u00fa\u00f1ez FJ, MG. DOI: Functional assay to of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models. Alghamri MS, Kamran N, Castro MG. Methods Enzymol. 2020;632:215-228. DOI: [10.1016/bs.mie.2019.05.047](https://www.doi.org/10.1016/bs.mie.2019.05.047) Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models. Alghamri MS, N\u00fa\u00f1ez FJ, Kamran N, Carney S, Altshuler D, Lowenstein PR, Castro MG. Methods Enzymol. 2020;631:91-106. DOI: [10.1016/bs.mie.2019.05.032](https://www.doi.org/10.1016/bs.mie.2019.05.032) 2019 Engineering patient-specific cancer immunotherapies. Scheetz L, Park KS, Li Q, Lowenstein PR, Castro MG, Schwendeman A, Moon JJ. Nat Biomed D, Nu\u00f1ez FM, Altshuler D, Doherty R, Kuai R, Yu M, Kamran N, Edwards M, Moon JJ, Lowenstein PR, Castro MG, Schwendeman A. ACS Nano. 2019 Feb 26;13(2):1365-1384. DOI: [10.1021/acsnano.8b06842](https://www.doi.org/10.1021/acsnano.8b06842) IDH1-R132H as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. N\u00fa\u00f1ez Mendez Kadiyala P, Alghamri C, Calinescu AA, Kamran N, Saxena M, Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA, Tagett R, Venneti S, Brosnan-Cashman J, Meeker A, Gorbunova V, Zhao L, Kremer DM, Zhang L, Lyssiotis CA, Jones L, Herting CJ, Ross JL, Hambardzumyan D, Hervey-Jumper S, Figueroa ME, Lowenstein PR, Castro MG. Sci Transl Med. 2019 Feb 13;11(479):eaaq1427. DOI: [10.1126/scitranslmed.aaq1427](https://www.doi.org/10.1126/scitranslmed.aaq1427) Evaluation Mendez FM, Garcia-Fabiani MB, Pardo J, Edwards M, Lowenstein PR, Castro MG. J Vis Exp. 2019 Jan 9;(143):10.3791/58931. DOI: [10.3791/58931](https://www.doi.org/10.3791/58931) 2018 Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and bevacizumab. Yadav VN, Altshuler D, Kadiyala P, Koschmann C, Oncol. 2018 Sep 3;20(10):1356-1367. DOI: [10.1093/neuonc/noy055](https://www.doi.org/10.1093/neuonc/noy055) new therapeutic target for glioma. Haase S, Garcia-Fabiani MB, Carney S, Altshuler D, N\u00fa\u00f1ez FJ, M\u00e9ndez FM, N\u00fa\u00f1ez F, Lowenstein PR, MG. Opin Ther Targets. 2018 Jul;22(7):599-613. DOI: [10.1080/14728222.2018.1487953](https://www.doi.org/10.1080/14728222.2018.1487953) Immature tumor microenvironment: Implications for immunotherapy. Kamran N, Chandran M, MG. Clin Immunol. 2018 Apr;189:34-42. DOI: [10.1016/j.clim.2016.10.008](HTTPS://WWW.DOI.ORG/10.1016/j.clim.2016.10.008) Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. Lowenstein PR, Castro MG. Clin Immunol. 2018 Apr;189:43-51. DOI: [10.1016/j.clim.2017.07.006](https://www.doi.org/10.1016/j.clim.2017.07.006) Current state immunotherapy for glioma. Kamran N, Alghamri MS, Nunez FJ, Shah D, Asad AS, Candolfi M, Altshuler D, Lowenstein PR, Castro MG. Immunotherapy. 1;10(4):317-339. N\u00fa\u00f1ez Zorrilla-Veloz RI, Lowenstein PR, 29;(131):57016. DOI: Li Y, Sierra M, Alghamri MS, Kadiyala P, Appelman HD, Edwards M, Lowenstein 2017 Dec 14;7(3):e1408750. PTEN loss as an early event. Koschmann C, Farooqui Z, Kasaian K, Cao X, Zamler S, Hervey-Jumper S, Garton H, Muraszko K, Franchi L, Robertson PL, Leonard M, Opipari V, Castro MG, Lowenstein PR, Chinnaiyan M, Shah D, Mineharu Y, Yadav VN, Koschmann C, Asad AS, Biol Ther. Hypoxic Stress is Controlled Feedback Mechanism. Calinescu AA, Tran D, Zamler DB, Doherty R, Srikanth M, Lowenstein PR, MG. Cancer Res. 2017 Mar 1;23(5):1250-1262. DOI: [10.1158/1078-0432.CCR-15-2888](HTTPS://WWW.DOI.ORG/10.1158/1078-0432.CCR-15-2888) Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer. Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman JA, Meeker AK, Lowenstein PR, Jan of Immune-Stimulatory Gene Therapy. Kamran N, Kadiyala P, Saxena M, Candolfi M, Li Y, Moreno-Ayala MA, Raja N, Shah D, Lowenstein PR, Castro Yadav AC, Mikkelsen T, PR. 2016 Dec 13;7(50):83701-83719. DOI: [10.18632/oncotarget.13295](https://www.doi.org/10.18632/oncotarget.13295) C, Zamler D, MacKay A, Robinson Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG. Oncotarget. 2016 Oct 4;7(40):65696-65706. DOI: [10.18632/oncotarget.11602](HTTPS://WWW.DOI.ORG/10.18632/oncotarget.11602) Recent advances and N, Calinescu A, Candolfi Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, MG. Expert Novel Vaccines for Gliomas. Lowenstein PR, Castro MG. Clin Cancer Res. 2016 Oct 1;22(19):4760-4762. DOI: [10.1158/1078-0432.CCR-16-1477](https://www.doi.org/10.1158/1078-0432.CCR-16-1477) Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery tool. Wilson TJ, Zamler DB, Doherty R, Castro MG, Lowenstein PR. Oncotarget. 2016 Sep 27;7(39):63020-63041. DOI: [10.18632/oncotarget.11589](https://www.doi.org/10.18632/oncotarget.11589) Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn \"On\" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model. VanderVeen N, Raja N, Yi E, Appelman H, Ng P, Palmer D, Zamler D, Dzaman M, Lowenstein PR, Castro MG. Hum Gene Ther Methods. 2016 Jun;27(3):98-111. DOI: [10.1089/hgtb.2015.168](HTTPS://WWW.DOI.ORG/10.1089/hgtb.2015.168) ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. Koschmann C, Lowenstein PR, Castro MG. Mol Cell Oncol. 2016 Apr 27;3(3):e1167158. DOI: [10.1080/23723556.2016.1167158](HTTPS://WWW.DOI.ORG/10.1080/23723556.2016.1167158) Natural Chockley P, Zamler PR. Oncoimmunology. 2016 Mar 16;5(6):e1163461. DOI: [10.1080/2162402X.2016.1163461](https://www.doi.org/10.1080/2162402X.2016.1163461) ATRX loss promotes tumor growth and impairs end joining DNA repair in glioma. Koschmann C, Calinescu AA, Nunez FJ, Mackay F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, Roh S, Zhao L, Appelman H, Ferguson D, Gorbunova V, Meeker A, Jones C, Lowenstein PR, Castro MG. Sci Transl Med. 2016 Mar 2;8(328):328ra28. DOI: [10.1126/scitranslmed.aac8228](HTTPS://WWW.DOI.ORG/10.1126/scitranslmed.aac8228) Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. Kamran N, Candolfi M, Baker GJ, Ayala MM, Dzaman PR, Castro MG. Methods Mol Biol. 2016;1382:467-82. DOI: [10.1007/978-1-4939-3271-9_31](HTTPS://WWW.DOI.ORG/10.1007/978-1-4939-3271-9_31) The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors. Lowenstein PR, Castro "}